Letter by Kurtoglu et al Regarding Article, “Asymmetric Dimethylarginine in Response to Recombinant Tissue-Type Plasminogen Activator and Erythropoietin in Acute Stroke” | Zendy

Ertuğrul Kurtoğlu | Zendy; Şevket Balta | Zendy; İsa Sıncer | Zendy; Hasan Korkmaz | Zendy

Open Access

Letter by Kurtoglu et al Regarding Article, “Asymmetric Dimethylarginine in Response to Recombinant Tissue-Type Plasminogen Activator and Erythropoietin in Acute Stroke”

Author(s) -

Ertuğrul Kurtoğlu,

Şevket Balta,

İsa Sıncer,

Hasan Korkmaz

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.003236

Subject(s) - medicine , erythropoietin , asymmetric dimethylarginine , plasminogen activator , placebo , recombinant dna , acute stroke , tissue plasminogen activator , cardiology , pathology , alternative medicine , biochemistry , chemistry , amino acid , arginine , gene

We read the article by Worthmann et al1 with interest. The authors investigated whether the combination of recombinant tissue-type plasminogen activator (rtPA) and erythropoietin (EPO) increases the release of endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). The patients were divided into 4 groups according to treatment: placebo, EPO, rtPA+placebo, and EPO+rtPA. They found that ADMA levels increased during the observation time in the EPO, the EPO+rtPA, and the placebo groups, whereas a treatment effect on ADMA levels was revealed only in the rtPA+placebo group when adjusted for age and infection at …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research